Understanding the factors influencing pharmacokinetics of tacrolimus
DOI:
https://doi.org/10.18203/2320-6012.ijrms20241273Keywords:
Tacrolimus, Immunosuppression, Pharmacokinetics, FactorsAbstract
Tacrolimus, a potent calcineurin inhibitor integral to immunosuppressive regimens, exhibits complex pharmacokinetics influenced by diverse factors and understanding these factors is crucial for safety, efficacy and dose optimisation. Genetic variations, particularly in CYP3A enzyme systems and P- Glycoprotein, contribute significantly to inter-individual variability in tacrolimus metabolism. Polymorphisms in these systems alter drug bioavailability, impacting clinical outcomes. Ethnicity further compounds this variability, with distinct genetic profiles leading to differential drug responses. Notably, black patients, often characterized by CYP3A5 expressor status, may have higher drug clearance. Age-related changes in tacrolimus clearance highlights the discrepancies in elderly and paediatric populations. On the other hand, prediction of gender-specific differences is difficult due to lack of evidence. Body composition, specifically variations in fat and muscle mass, significantly impacts drug distribution and clearance. Obesity, associated with altered CYP3A activity, results in decreased drug clearance, emphasizing the importance of accounting for body composition in dosing calculations. Pregnancy -induced physiological changes affect tacrolimus absorption, distribution, metabolism, and excretion, necessitating careful monitoring and dose adjustments in pregnant individuals. Dietary factors and drug interactions, particularly with CYP3A4 and P-glycoprotein, further contribute to the intricate web of variables influencing tacrolimus pharmacokinetics. In conclusion, this review sheds light on the multifaceted factors influencing tacrolimus pharmacokinetics, providing essential insights for clinicians to tailor individualized dosing regimens and enhance therapeutic efficacy while minimizing the risk of adverse events.
Metrics
References
Letko E, Bhol K, Pinar V, Foster CS, Ahmed AR. Tacrolimus (FK 506). Annals of Allergy, Asthma & Immunology. 1999;83(3):179–90.
Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artificial organs. 2020;44(2):140-52.
Araya AA, Tasnif Y. Tacrolimus. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544318/. Accessed on 15 January 2024.
Ohtsuki M, Morimoto H, Nakagawa H. Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: review on safety and benefits. The Journal of dermatology. 2018;45(8):936-42.
Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Therapeutic drug monitoring. 1995;17(6):584-91.
Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clinical pharmacokinetics. 1995;29:404-30.
Christians U, Strom T, Zhang YL, Steudel W, Schmitz V, Trump S, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Therapeutic drug monitoring. 2006;28(1):039-044.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical pharmacokinetics. 2004;43:623-53.
Yu M, Liu M, Zhang W, Ming Y. Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation. Current drug metabolism. 2018;19(6):513-22.
Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clinical pharmacokinetics. 2010;49:141-75.
Lesche D, Sigurdardottir V, Setoud R, Oberhänsli M, Carrel T, Fiedler GM, et al. CYP3A5* 3 and POR* 28 genetic variants influence the required dose of tacrolimus in heart transplant recipients. Therapeutic drug monitoring. 2014;36(6):710-5.
Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transplant International. 2008;21(9):879-91.
MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. American Journal of Transplantation. 2004;4(6):914-9.
Tornatore KM, Meaney CJ, Attwood K, Brazeau DA, Wilding GE, Consiglio JD, et al. Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2022;42(2):94-105.
Tornatore KM, Attwood K, Venuto RC, Murray B. Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: Implications for health inequities. Clinical and Translational Science. 2023;16(5):861-71.
Machado CG, Calado RT, Garcia AB, Falcão RP. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Brazilian journal of medical and biological research. 2003;36:1653-57.
Velickovic-Radovanovic R, Mikov M, Catic-Djordjevic A, Stefanovic N, Mitic B, Paunovic G, et al. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients. European journal of drug metabolism and pharmacokinetics. 2015;40(1):95-102.
Velicković-Radovanović R, Mikov M, Paunović G, Djordjević V, Stojanović M, Cvetković T, et al. Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients. Gender medicine. 2011;8(1):23-31.
Francke MI, Visser WJ, Severs D, de Mik-van Egmond AM, Hesselink DA, De Winter BC. Body composition is associated with tacrolimus pharmacokinetics in kidney transplant recipients. European Journal of Clinical Pharmacology. 2022;78(8):1273-87.
Han SS, Kim DH, Lee SM, Han NY, Oh JM, Ha J, et al. Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants. Kidney research and clinical practice. 2012;31(3):157-62.
Shah S, Verma P. Overview of pregnancy in renal transplant patients. International journal of nephrology. 2016; 2016.
Schagen MR, Ulu AN, Francke MI, van de Wetering J, van Buren MC, Schoenmakers S, et al. Modelling changes in the pharmacokinetics of tacrolimus during pregnancy after kidney transplantation: A retrospective cohort study. British Journal of Clinical Pharmacology. 2024;90(1):176-88.
Zheng S, Easterling TR, Umans JG, Miodovnik M, Calamia JC, Thummel KE, et al. Pharmacokinetics of tacrolimus during pregnancy. Therapeutic drug monitoring. 2012;34(6):660-70.
Bekersky I, Dressler D, Mekki QA. Effect of low‐and high‐fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. The Journal of Clinical Pharmacology. 2001;41(2):176-82.
Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. The Journal of Clinical Pharmacology. 2001;41(3):289-97.
van Gelder T. Drug interactions with tacrolimus. Drug safety. 2002;25:707-12.
Rančić NK, Vavić NN, Kovačević AM, Mikov MM, Dragojević SV. Drug-drug interactions of tacrolimus. Hospital Pharmacology-International Multidisciplinary Journal. 2015;2(3):291-6.
Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clinical pharmacokinetics. 1999;37:399-31.
Downloads
Published
How to Cite
Issue
Section
